XML 16 R7.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 25, 2022
Sep. 26, 2021
Cash flows from operating activities:    
Net loss $ (136,630) $ (86,994)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 33,870 25,558
Amortization of lease acquisition 402 300
Amortization of loan origination fees 112 68
Loss on fixed asset disposal 41 56
Stock-based compensation 62,973 6,104
Impairment of long-lived assets and closed-store costs 1,845 4,415
Non-cash restructuring charges 9,841 0
Deferred income tax expense 59 0
Change in fair value of contingent consideration liability (2,155) 0
Change in fair value of preferred stock warrant liability 0 608
Changes in operating assets and liabilities:    
Accounts receivable (1,935) (1,363)
Tenant improvement receivables 1,547 (10,830)
Inventory (299) (213)
Prepaid expenses and other assets (1,639) 146
Accounts payable (822) 3,539
Accrued payroll and benefits (3,129) 10,396
Accrued expenses 205 (3,384)
Gift card and loyalty liability (196) (988)
Other non-current liabilities (517) 0
Deferred rent liability 12,346 16,367
Net cash used in operating activities (24,081) (36,215)
Cash flows from investing activities:    
Purchase of property and equipment (65,979) (60,070)
Purchase of intangible assets (3,552) (5,438)
Acquisition, net of cash and cash equivalents acquired 0 (3,340)
Security and landlord deposits 161 242
Lease acquisition costs (1,625) (1,140)
Net cash used in investing activities (70,995) (69,746)
Cash flows from financing activities:    
Proceeds from preferred stock issuance, net of issuance costs 0 113,811
Proceeds from stock option exercise 3,978 25,347
Deferred offering costs paid 0 (3,793)
Proceeds from related party loan 0 5,158
Proceeds from exercise of warrants 0 32
Net cash provided by financing activities 3,978 140,555
Net (decrease) increase in cash and cash equivalents and restricted cash (91,098) 34,594
Cash and cash equivalents and restricted cash—beginning of year 472,299 102,765
Cash and cash equivalents and restricted cash—end of period 381,201 137,359
Supplemental disclosure of cash flow information    
Purchase of property and equipment accrued in accounts payable and accrued expenses 702 2,431
Non-cash investing and financing activities    
Deferred offering costs not yet paid 0 1,246
Initial liability associated with Series J warrants 0 4,953
Acquisition non-cash consideration 0 30,704
Initial liability associated with contingent consideration $ 0 $ 16,440